Table 1.
Characteristic | 2004–05 | 2006–07 | 2008–09 | 2010–11 |
---|---|---|---|---|
Age (year) | ||||
Mean | 64.8 | 66.6 | 68.7 | 70.9 |
Rangea | 52 to >90 | 54 to >90 | 56 to >90 | 58 to >90 |
Female, n (%) | 2,882 (56.4) | No change | No change | No change |
Male, n (%) | 2,232 (43.6) | |||
White, n %) | 5,026 (98.3) | No change | No change | No change |
Non-white, n (%) | 86 (1.7) | |||
Educationb (highest qualification), n (%) | No change | No change | No change | |
Higher education | 1,449 (28.3) | |||
High school | 2,004 (39.2) | |||
No qualifications | 1,660 (32.5) | |||
Total net household financial wealth (£) | ||||
Median | 208,664 | 230,406 | 226,242 | 231,365 |
Range | −43,470–9,297,227 | −83,903–208 × 105 | −150,171–208 × 105 | −92,902–6,557,635 |
One or more conditions, n (%) | 1,998 (39) | 2,738 (54) | 2,961 (58) | 2,290 (44.8) |
Number of conditions for which participants were eligible | ||||
Meanc | 1 | 1 | 1 | 1 |
Range | 0–6 | 0–4 | 0–4 | 0–3 |
Number of indicators for which participants were eligible | ||||
Meanc | 1 | 1 | 1 | 1 |
Range | 0–13 | 0–7 | 0–8 | 0–8 |
Clinical incidenced over 2 years, n (%) | ||||
Cerebrovascular disease | 32 (0.7) | 53 (1.1) | 60 (1.2) | |
Depression | 65 (1.3) | 53 (1.1) | ||
Falls | 254 (5.0) | |||
Ischaemic heart disease | 183 (3.7) | |||
Osteoarthritis | 415 (11.1) | 372 (9.7) | 415 (11.1) | |
Pain | 80 (1.6) | |||
Hypertension | 253 (8.5) | 453 (13.5) | 334 (10.7) | |
Clinical prevalence, n (%) | ||||
Osteoporosis | 295 (5.8) | 338 (6.6) | 395 (7.7) | 475 (9.3) |
Cataract | 512 (10.0) | 803 (15.7) | 875 (17.1) | 1,095 (21.4) |
Diabetes mellitus | 351 (6.9) | 447 (8.7) | 542 (10.6) | 634 (12.4) |
aAll 95 respondents with age >90 years had exact age withheld from released data.
bHigher education = degree or higher education below degree; high school = secondary school or equivalent. Information was missing on education for one participant.
cRounded to nearest whole number.
dIncidence rates refer to ∼2 years since the previous survey wave or have been adjusted for 2 years.